EP Patent

EP3424524A2 — Cancer rna-vaccine

Assigned to Curevac SE · Expires 2019-01-09 · 7y expired

What this patent protects

The present invention provides artificial nucleic acid molecules encoding at least one antigenic peptide or protein and at least one additional sequence targeting the antigenic peptides or proteins to cellular compartments of interest. Further, the invention provides pharmaceutic…

USPTO Abstract

The present invention provides artificial nucleic acid molecules encoding at least one antigenic peptide or protein and at least one additional sequence targeting the antigenic peptides or proteins to cellular compartments of interest. Further, the invention provides pharmaceutical compositions or vaccines and kits comprising said nucleic acid molecules. The nucleic acid moleclues, pharmaceutical compositions or vaccines and kits are useful for treating a variety of diseases such as cancer, infectious diseases, autoimmune diseases, allergies or graft-versus host disease.

Drugs covered by this patent

Patent Metadata

Patent number
EP3424524A2
Jurisdiction
EP
Classification
—
Expires
2019-01-09
Drug substance claim
No
Drug product claim
No
Assignee
Curevac SE
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.